Floatz logo

hh2710

Advanced Tumors

Haihe Biopharma Co., Ltd.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

928 Active assets in the Advanced Tumors cohort.

View all 50

Same molecule, other indications

hh2710 is also rated in:

Erdheim-Chester diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →